Blood Test Measures Hodgkin’s Chemotherapy Success
|
By HospiMedica International staff writers Posted on 06 Mar 2013 |
|
A cheap and easy to use diagnostic test helps determine the success of chemotherapy in patients enduring Hodgkin’s lymphoma (HL).
Researchers at the Queensland Institute of Medical Research (QIMR; Brisbane, Australia), the University of Melbourne (Australia), and other institutions prospectively measured serum CD163 (sCD163) and the Hodgkin-Reed-Sternberg (HRS)-specific serum protein sTARC in 221 samples taken from 47 patients with HL, and 21 healthy participants. Blood was drawn at five fixed time-points prior, during, and after first-line therapy. The results were compared with radiological assessment and plasma Epstein-Barr virus DNA (EBV-DNA). The researchers also examined potential sources of circulating CD163, as well as immunosuppressive properties of CD163.
The results showed that prior to therapy, both sCD163 and sTARC were markedly elevated compared with healthy and complete remission samples; sCD163 better reflected tumor burden during therapy, and sTARC presenting greater value upon completion of therapy. Additionally, sCD163 correlated with plasma EBV-DNA, and was associated with B symptoms, stage, and lymphopenia. The researchers found that the combination of both proteins was more informative as a disease response biomarker than either marker alone, in early and advanced disease during first-line therapy for classical HL. The study was published in the February 2013 issue of Clinical Cancer Research.
“This has the potential to be a huge aid for doctors in their decision making and a faster and less invasive process for the patients. Up until now, clinicians have relied on scans to help them judge how well people are responding to chemotherapy,” said lead author Professor Maher Gandhi, PhD, of the QIMR Clinical Immunohaematology Laboratory. “This discovery means we can work towards using simple blood tests to provide quicker, cheaper, and more regular monitoring of how a person is responding to treatment.”
Response biomarkers for classical HL might arise from Hodgkin-Reed-Sternberg (HRS) cells or nonmalignant tumor-infiltrating cells. While HRS cells are sparse within the diseased node, benign CD163(+) M2 tissue-associated macrophages (TAM) are prominent. It is known that CD163(+) cells within the malignant node may be prognostic, but until now there has been no data on serum CD163.
Related Links:
Queensland Institute of Medical Research
University of Melbourne
Researchers at the Queensland Institute of Medical Research (QIMR; Brisbane, Australia), the University of Melbourne (Australia), and other institutions prospectively measured serum CD163 (sCD163) and the Hodgkin-Reed-Sternberg (HRS)-specific serum protein sTARC in 221 samples taken from 47 patients with HL, and 21 healthy participants. Blood was drawn at five fixed time-points prior, during, and after first-line therapy. The results were compared with radiological assessment and plasma Epstein-Barr virus DNA (EBV-DNA). The researchers also examined potential sources of circulating CD163, as well as immunosuppressive properties of CD163.
The results showed that prior to therapy, both sCD163 and sTARC were markedly elevated compared with healthy and complete remission samples; sCD163 better reflected tumor burden during therapy, and sTARC presenting greater value upon completion of therapy. Additionally, sCD163 correlated with plasma EBV-DNA, and was associated with B symptoms, stage, and lymphopenia. The researchers found that the combination of both proteins was more informative as a disease response biomarker than either marker alone, in early and advanced disease during first-line therapy for classical HL. The study was published in the February 2013 issue of Clinical Cancer Research.
“This has the potential to be a huge aid for doctors in their decision making and a faster and less invasive process for the patients. Up until now, clinicians have relied on scans to help them judge how well people are responding to chemotherapy,” said lead author Professor Maher Gandhi, PhD, of the QIMR Clinical Immunohaematology Laboratory. “This discovery means we can work towards using simple blood tests to provide quicker, cheaper, and more regular monitoring of how a person is responding to treatment.”
Response biomarkers for classical HL might arise from Hodgkin-Reed-Sternberg (HRS) cells or nonmalignant tumor-infiltrating cells. While HRS cells are sparse within the diseased node, benign CD163(+) M2 tissue-associated macrophages (TAM) are prominent. It is known that CD163(+) cells within the malignant node may be prognostic, but until now there has been no data on serum CD163.
Related Links:
Queensland Institute of Medical Research
University of Melbourne
Gold Member
STI Test
Vivalytic Sexually Transmitted Infection (STI) Array
Gold Member
12-Channel ECG
CM1200B
Fetal Monitor
BT-380
Multi-Chamber Washer-Disinfector
WD 390
Latest Critical Care News
- Smartphone Heart Rhythm App Reduces Unnecessary Cardioversion Procedures
- Bedside CSF Monitor Detects Early Infection in Fluid Drains
- Wearable Ultrasound Patch Noninvasively Paces Heart to Stabilize Arrhythmias
- New Practice Guidance Supports Prostatic Artery Embolization for BPH Symptoms
- AI ECG Tool Detects Cardiac Amyloidosis for Early Screening
- Cuffless Wearable Enables Continuous Blood Pressure Monitoring for Hypertension Care
- AI-Guided System Supports Cardiac Ultrasound Training on Cart-Based Systems
- AI ECG Index Tracks Pubertal Maturation in Children and Adolescents
- Noninvasive AI Tool Enables Pressure-Guided Heart Failure Management
- Regenerative Therapies Aim to Support Recovery After Traumatic Brain Injury
- Ring-Type Cuffless Monitor Becomes First Added to Official Hypertension Guidelines
- “Intelligent Tattoo” Method Detects Early Melanoma Signals
- Implantable Wireless Light Device Advances Bladder Cancer Treatment
- Reusable Intermittent Catheters Reduce Antibiotic Use Without Increasing Urinary Tract Infections
- Smart Wristband Technology Detects Cardiac Arrest and Alerts Responders
- FDA-Cleared Home Sleep Test Enables Multi-Night Diagnosis of Sleep Apnea
Channels
Artificial Intelligence
view channel
AI Platform Supports Noninvasive Remote Hemodynamic Monitoring in Heart Failure
Heart failure remains a leading cause of hospitalization in adults over 65, affecting more than 6.7 million people in the U.S. Clinicians often lose visibility into hemodynamic deterioration once patients... Read more
AI Tool Predicts Unplanned Care and Symptom Burden in Cancer Survivors
Unplanned emergency visits and hospitalizations remain common in cancer survivorship, when routine clinical contact often tapers while new symptoms emerge. These events reflect unmet needs and disrupt... Read more
Surgical Techniques
view channel
CE-Marked Ultrasonic Shears Streamline Breast and Thyroid Surgery
Thyroid and breast surgeries are often performed in confined anatomical spaces near critical structures, making precise dissection and controlled thermal management essential. As the global disease burden... Read more
3D Map of Heart Electrical Wiring Aims to Guide Congenital Heart Repair
Tetralogy of Fallot is one of the most common congenital heart problems and often requires surgery in infancy. Many survivors later develop conduction abnormalities because the cardiac electrical system... Read more
Patient Care
view channel
AI Avatar Doctor Improves Patient Understanding Before Radiotherapy
Radiation oncology consultations require patients to grasp complex concepts quickly, yet anxiety and information overload often undermine understanding and informed consent. Poor comprehension can also... Read more
Wearable Sleep Data Predict Adherence to Pulmonary Rehabilitation
Chronic obstructive pulmonary disease (COPD) is a long-term lung disorder that makes breathing difficult and often disturbs sleep, reducing energy for daily activities. Limited engagement in pulmonary... Read more
Health IT
view channel
AI-Native EHR Achieves EU Medical Device Certification
InterSystems (Boston, MA, USA) announced that its IntelliCare electronic health record (EHR) solutions have been certified as Class IIa medical devices under the European Union Medical Device Regulation... Read more
EHR-Integrated Screening Workflow Detects Cognitive Impairment at Admission
Cognitive impairment involves difficulties with thinking, learning, memory, and decision-making, and is more common in older adults. In U.S. hospitals, more than 40% of admitted older adults have dementia,... Read more
Point of Care
view channel
Portable MRI System Accelerates Emergency Brain Imaging and Triage
Emergency departments frequently face delays accessing conventional magnetic resonance imaging (MRI) for patients with suspected neurological emergencies. Such waits can slow triage, prolong boarding,... Read more
Point-of-Care Viscoelastic Testing System Supports Obstetric Bleeding Management
HemoSonics (Durham, NC, USA) announced on May 5, 2026 that the company's Quantra Hemostasis System for Obstetric Procedures won Silver in the 2026 Edison Awards in the Women’s Health and Reproductive Innovations... Read more
Business
view channel
Endologix Adds FDA-Cleared Peripheral Thrombectomy System
Endologix (Santa Rosa, CA, USA) has acquired the Pounce Thrombectomy System from Surmodics, with the transaction closing on May 18, 2026. The FDA-cleared system is indicated for the non-surgical removal... Read more
